Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype

Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype

To date, available treatment strategies for multiple sclerosis (MS) are ineffective in preventing or reversing progressive neurologic deterioration, creating a high, and unmet medical need. One potential way to fight MS may be by limiting the detrimental effects of reactive astrocytes, a key patholo...

Full description

Bibliographic Details
Main Authors: Alwin Kamermans, Tom Verhoeven, Bert van het Hof, Jasper J. Koning, Lauri Borghuis, Maarten Witte, Jack van Horssen, Helga E. de Vries, Merel Rijnsburger
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
inflammation
melanocortin
melanocortin receptor-4
astrocyte
macrophage
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02312/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.02312/full

Similar Items